JP2015091877A5 - - Google Patents

Download PDF

Info

Publication number
JP2015091877A5
JP2015091877A5 JP2015021023A JP2015021023A JP2015091877A5 JP 2015091877 A5 JP2015091877 A5 JP 2015091877A5 JP 2015021023 A JP2015021023 A JP 2015021023A JP 2015021023 A JP2015021023 A JP 2015021023A JP 2015091877 A5 JP2015091877 A5 JP 2015091877A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
amount
present
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015021023A
Other languages
English (en)
Japanese (ja)
Other versions
JP6014695B2 (ja
JP2015091877A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015091877A publication Critical patent/JP2015091877A/ja
Publication of JP2015091877A5 publication Critical patent/JP2015091877A5/ja
Application granted granted Critical
Publication of JP6014695B2 publication Critical patent/JP6014695B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015021023A 2009-07-31 2015-02-05 癌および他の疾患または障害の治療のための医薬組成物 Active JP6014695B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31
US61/230,212 2009-07-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012522810A Division JP2013500965A (ja) 2009-07-31 2010-07-28 癌および他の疾患または障害の治療のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2015091877A JP2015091877A (ja) 2015-05-14
JP2015091877A5 true JP2015091877A5 (https=) 2015-12-17
JP6014695B2 JP6014695B2 (ja) 2016-10-25

Family

ID=42697590

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012522810A Pending JP2013500965A (ja) 2009-07-31 2010-07-28 癌および他の疾患または障害の治療のための医薬組成物
JP2015021023A Active JP6014695B2 (ja) 2009-07-31 2015-02-05 癌および他の疾患または障害の治療のための医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012522810A Pending JP2013500965A (ja) 2009-07-31 2010-07-28 癌および他の疾患または障害の治療のための医薬組成物

Country Status (30)

Country Link
US (3) US20110039826A1 (https=)
EP (1) EP2459173B1 (https=)
JP (2) JP2013500965A (https=)
KR (1) KR101762285B1 (https=)
CN (2) CN103893186B (https=)
AR (1) AR077436A1 (https=)
AU (1) AU2010276741B2 (https=)
BR (1) BR112012002265B8 (https=)
CA (1) CA2769531C (https=)
CL (1) CL2012000261A1 (https=)
CO (1) CO6612185A2 (https=)
CR (1) CR20120084A (https=)
EA (1) EA025277B1 (https=)
EC (1) ECSP12011703A (https=)
GE (1) GEP201606513B (https=)
IL (1) IL217839A (https=)
IN (1) IN2012DN01237A (https=)
JO (1) JO3434B1 (https=)
MA (1) MA33533B1 (https=)
MX (2) MX2012001196A (https=)
MY (1) MY174084A (https=)
NZ (1) NZ598096A (https=)
PE (1) PE20120788A1 (https=)
SG (2) SG177751A1 (https=)
TN (1) TN2012000046A1 (https=)
TW (1) TWI522357B (https=)
UA (1) UA110463C2 (https=)
UY (1) UY32822A (https=)
WO (1) WO2011014248A1 (https=)
ZA (1) ZA201200944B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005243175B2 (en) * 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
RU2535032C2 (ru) 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
BR112012020557A8 (pt) 2010-02-19 2018-01-02 Millennium Pharm Inc formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface
CN121941495A (zh) 2023-10-03 2026-04-28 武田药品工业株式会社 用于治疗小细胞肺癌的阿立塞替和紫杉醇
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
AU784971B2 (en) 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
KR20030019327A (ko) * 2000-03-24 2003-03-06 아이박스 리서치 인코포레이티드 탁산-기저 조성물을 안정시키는 금속염의 용도
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2005243175B2 (en) * 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
EA200870117A1 (ru) * 2005-12-23 2008-12-30 Смитклайн Бичам Корпорейшн Азаиндоловые ингибиторы аурора-киназ
JP2009542664A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション P53活性を増大させる置換されたピペリジンの使用の方法
PT2046292E (pt) * 2006-07-21 2010-04-26 Novartis Ag Formulações de éteres benzimidazolil-piridílicos
US7718648B2 (en) * 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
RU2535032C2 (ru) * 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
BR112012020557A8 (pt) * 2010-02-19 2018-01-02 Millennium Pharm Inc formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio

Similar Documents

Publication Publication Date Title
JP2015091877A5 (https=)
HRP20201681T1 (hr) Inhibitor aurora a kinaze
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
AR077436A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables.
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
HRP20221294T1 (hr) Neuroaktivni steroidi, njihovi pripravci i uporabe
JP2019524883A5 (https=)
JP2016515560A5 (https=)
RU2011127468A (ru) Технецкий- и рений-бис(гетероарильные) комплексы и методы их применения для ингибирования psma
JP2014508804A5 (https=)
HRP20210183T1 (hr) 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate
TN2015000445A1 (en) Derivatives of dolastatin 10 and auristatins
JP2015512413A5 (https=)
JP2016531126A5 (https=)
JP2019535723A5 (https=)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2017507175A5 (https=)
JP2020097577A5 (https=)
JP2017501237A5 (https=)
JP2015098469A5 (https=)
JP2016528273A5 (https=)
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
EA201691342A1 (ru) Пиразолоновые соединения и их применение
JP2017505785A5 (https=)